好久没有去官网看，今天去瞄了一眼，嗯还算好消息。
MARLBOROUGH, Mass. — April 16, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the second patient was dosed in the Company’s Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient is recovering uneventfully.
RPE移植临床I/II - 4/16日先进细胞公司对第二例干性黄斑萎缩病人注射从胚胎提取的RPE细胞，病人目前尚在安全恢复期。
“We are very pleased to announce that the treatment of the second dry AMD patient went very well, without any complications,” said Gary Rabin, chairman and CEO of ACT. “We are delighted with our ongoing progress in all of our clinical trials using our stem cell-derived RPE cells to treat forms of macular degeneration. So far, there have not been any complications or side effects due to the stem cell-derived RPE cells, and we will continue monitoring the patients for safety, tolerability and efficacy of this therapy.”
先进细胞公司CEO表示治疗非常顺利，目前尚无并发症或RPE细胞移植引起的副作用。实验室将持续关注此项治疗的安全性、耐受性以及效果。
The dry AMD trial is one of three clinical trials being carried out by the company in the U.S. and in Europe. Each trial will enroll 12 patients, with cohorts of three patients in an ascending dosage format.
在美国和欧洲同时还有2项相关实验正在进行。三项实验中将招募12名病人，群组内注射剂量逐渐递增。
These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or Stargardt’s macular dystrophy (SMD) at 12 months, the study’s primary endpoint.
12月内将完成该项针对干性萎缩和少年黄斑病变项目的首轮实验。
原文链接: http://www.advancedcell.com/news-and-media/press-releases/act-announces-second-patient-with-dry-amd-treated-in-us-clinical-trial-with-rpe-cells-derived-from-embryonic-stem-cells/index.asp
看到其他治疗版各位朋友的开心劲也很受感染，默默关注着并祈愿每个方面的希望都在继续 |
